Elypta Company

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
Technology: Others
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Stockholm, Stockholms Lan, Sweden
Founded Date: 2017-05-01
Employees Number: 1-10
Funding Status: Seed

Visit Website
Register and Claim Ownership